Auf der Suche nach einer alternativen Therapie bei Patientinnen mit zytostatisch ausbehandeltem Mammakarzinom setzten wir Tamoxifen, Vindesin und Carmustin (BCNU) ein. 27 Patientinnen wurden in eine Studie aufgenommen, die eine Stufe I mit Tamoxifen allein und eine Stufe II mit Vindesin, Carmustin, Tamoxifen umfaßte. In der Stufe I mit Tamoxifen reagierten 7 von 14 (50%) und in der folgenden Stufe II mit Vindesin, Carmustin und Tamoxifen 4 von 20 (20%) Patientinnen mit einer Remission. Die mittlere Remissionsdauer betrug +7,4 bzw. +9,0 Monate. Die Ergebnisse zeigen, daß auch für Patientinnen mit weit fortgeschrittenem Mammakarzinom eine palliative Folgetherapie nach Behandlung mit Vincristin + Adriamycin + Cyclophospha-mid und 5-Fluorouracil + Methotrexat + Cyclophosphamid möglich ist.

Keywords:
Alternativbehandlung, Fortgeschrittenes Mammakarzinom, Vindesin, Carmustin (BCNU), Tamoxifen
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.